This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

One Short Seller's Take On Arena's Slow Belviq Launch

Stocks in this article: ARNA OREX VVUS

SAN DIEGO ( TheStreet) -- The number of prescriptions for Arena Pharmaceuticals' (ARNA - Get Report) weight-loss pill Belviq rose either 12% or 16% for the week ended July 12 -- the difference depends on which of the two major drug prescriptions data services (IMS Health or Symphony) you follow.

Either way, Belviq's launch is slow out of gate, says an institutional investor shorting shares of Arena. Here's his take:

While early, the prescription trends for Belviq -- launched without a restrictive risk management (REMS) plan -- are terrible.

Qsymia had a significant REMS, was first to market, couldn't do any sampling, and as is obvious to all, wasn't competent in their launch even given the challenges.

On the flip side, Arena and Eisai have had a year to sit back, watch, strategize, and so far, Belviq is a flop to say the least. Prescription data to date suggest Belviq is on the same initial slope as Qsymia when it launched (albeit left by a couple weeks and just slightly higher in total prescriptions.) But lost by many is the fact that relative to the apparent increase in prescriptions when compared to Qsymia, nearly 60 percent of Belviq's total prescriptions (TRx) for the last two weeks are for free drug (15-day trial.)

Vivus (VVUS - Get Report) is now in the hands of a much more competent management team and new independent directors like Alex Denner. A less restrictive REMS is already boosting prescriptions. Orexigen Therapeutics (OREX - Get Report) is likely coming in the near term. For all these reasons, Belviq is doomed here, as it should be, given its weak profile in comparison to the others weight-loss drugs.

Ultimately, I believe Orexigen will take the case with ease.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs